Jubilant Pharmova (530019) Q2 26/27 earnings summary

Executive summary

• Q2 FY27 consolidated revenue from operations was 23,700 million vs 19,664 million YoY, while profit for the period fell to 310 million from 1,199 million.

• H1 FY27 revenue was 45,994 million vs 38,671 million YoY; profit for the period was 874 million vs 2,224 million.

Financial highlights

• Q2 total income was 23,844 million vs 19,762 million YoY; PBT was 617 million vs 1,903 million.

• H1 PBT was 1,481 million vs 3,447 million YoY; exceptional items were 58 million for H1 FY27 vs nil in H1 FY26.

• Q2 EPS was 1.97 vs 7.59 YoY; H1 EPS was 5.54 vs 14.08.

Segment performance

• Q2 Radiopharma revenue was 10,093 million vs 8,971 million YoY; segment result was 698 million vs 955 million.

• Q2 Sterile Injectables CDMO revenue was 5,596 million vs 4,115 million; segment result was a loss of 42 million vs profit of 710 million.

• Q2 Generics revenue was 2,741 million vs 1,670 million; segment result was 51 million vs a loss of 3 million.

• Q2 Proprietary Novel Drugs segment result was a loss of 102 million vs a loss of 29 million; revenue was 2 million vs 1 million.